gdc
PSSGuide_2020

Drugs for Colorectal Cancer

Here are the drugs and financial support services available to patients receiving treatment for Colorectal Cancer.

Avastin (bevacizumab) Injection

Drug company: Genentech
866-422-2377

Avastin is a VEGF-specific angiogenesis inhibitor used as a first-line or second-line treatment for patients with metastatic colorectal cancer, together with IV chemotherapy. Avastin is also used as a second-line treatment, in combination with other types of chemotherapy, in patients with metastatic colorectal cancer whose disease progressed with a first-line Avastin-containing regimen.

Genentech provides 2 financial assistance programs for patients who are using Avastin:

Genentech BioOncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Avastin, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 120 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Avastin free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Camptosar (irinotecan hydrochloride injection)

Drug company: Pfizer
844-989-7284

Camptosar is a topoisomerase inhibitor used as a first-line therapy, in combination with a chemotherapy regimen, for patients with metastatic carcinoma of the colon or the rectum (colorectal cancer). Camptosar is also used for patients with metastatic carcinoma of the colon or rectum whose disease has returned or progressed after chemotherapy.

Pfizer provides 1 financial assistance program for patients using Camptosar:

Pfizer Patient Assistance Program

Patients who are prescribed a Pfizer specialty medicine, such as Camptosar, and meet certain income limits but have no drug perscription coverage or insufficient coverage to pay for Camptosar, can use this program to receive free medicine through their doctor’s office, at home, or possibly through their pharmacy.

Cyramza (ramucirumab)

Drug company: Eli Lilly
866-472-8663

Cyramza is a human VEGF receptor 2 antagonist used in combination with chemotherapy for patients with metastatic colorectal cancer that progressed during or after therapy with Avastin, Eloxatin, and a fluoropyrimidine.

Lilly PatientOne provides 2 financial assistance programs for patients using Cyramza:

Lilly PatientOne Co-pay Program

For patients with private insurance who cannot afford their copay, this program provides up to $25,000 annually so that the patient pays no more than $25 per dose of Cyramza.

Lilly Cares Foundation Patient Assistance Program

For eligible patients with no medical insurance (or those whose insurance does not cover drug therapy) and who have an annual household income of up to $62,450 for 1 person; $84,550 for 2 people; $106,650 for 3 people; $128,750 for 4 people; $150,850 for 5 people; $172,950 for 6 people, this program provides Cyramza at no cost.

Erbitux (cetuximab)

Drug company: Eli Lilly
866-472-8663

Erbitux is an EGFR antagonist used for the treatment of patients with KRAS wild-type, EGFR-expressing, metastatic colorectal cancer in combination with a chemotherapy regimen for first-line treatment, in combination with Camptosar for patients who cannot use Camptosar-based chemotherapy, or as a single drug for patients who have not benefited from Eloxatin- and Camptosar-based chemotherapy, or who cannot use Camptosar.

Lilly PatientOne provides 2 financial assistance programs for patients using Erbitux:

Lilly PatientOne Co-pay Program

For patients with private insurance who cannot afford their copay, this program provides up to $25,000 annually so that the patient pays no more than $25 per dose of Erbitux.

Lilly Cares Foundation Patient Assistance Program

For eligible patients with no medical insurance (or those whose insurance does not cover drug therapy) and a household income up to 500% or less of the federal poverty level, this program provides Erbitux at no cost.

Fusilev (levoleucovorin)

Drug company: Acrotech Biopharma
888-537-8277

Fusilev is a folate analog used in combination with chemotherapy for palliative treatment of patients with advanced metastatic colorectal cancer.

Acrotech Biopharma, through its Specialty Therapy Access Resources (STAR) program, offers 2 financial assistance programs for patients receiving Fusilev:

STAR Co-pay Assistance

Eligible, privately insured patients will pay $0 out of pocket for the first injection of Fusilev and then $25 for each subsequent injection, with a benefit of up to $10,000 per calendar year.

STAR Patient Assistance Program

This program provides Fusilev free of charge to enrolled patients who meet the income, insurance, and residency eligibility criteria.

Khapzory (levoleucovorin) for Injection

Drug company: Acrotech Biopharma
888-537-8277

Khapzory is a folate analog used, in combination with fluorouracil chemotherapy, for the treatment of patients with metastatic colorectal cancer. Khapzory is also used for the treatment of patients with osteosarcoma (bone cancer) after high-dose methotrexate therapy.

Acrotech Biopharma, through its Specialty Therapy Access Resources (STAR) program, offers 2 financial assistance programs for patients receiving Khapzory:

STAR Co-pay Assistance

Eligible, privately insured patients will pay $0 out of pocket for the first injection of Khapzory and then $25 for each subsequent injection, with a benefit of up to $10,000 per calendar year.

STAR Patient Assistance Program

This program provides Khapzory free of charge to enrolled patients who meet the income, insurance, and residency eligibility criteria.

Lonsurf (trifluridine + tipiracil) Tablets

Drug company: Taiho
844-824-4648

Lonsurf is a combination of a nucleoside metabolic inhibitor and a thymidine phosphorylase inhibitor used for patients with metastatic colorectal cancer who have previously received chemotherapy, an anti-VEGF biological therapy, and if their cancer is KRAS wild-type, an anti-EGFR therapy.

Taiho Oncology Patient Support provides 2 financial assistance programs for patients using Lonsurf:

Taiho Oncology Patient Support Co-pay Card

Patients with private insurance may be eligible to receive a copay card to help them to pay $30 out-of-pocket expenses for a treatment cycle of Lonsurf.

Taiho Oncology Patient Support Program

This program may provide Lonsurf free of charge for patients who have no insurance or insufficient prescription coverage and insufficient financial resources.

Mvasi (bevacizumab-awwb)

Drug company: Amgen
888-427-7478

Mvasi a biosimilar to Avastin, is a VEGF inhibitor used, in combination with chemotherapy, for first- or second-line treatment of patients with metastatic colorectal cancer, or used for second-line treatment after disease progression with a first-line bevacizumab-containing regimen.

Amgen offers 2 financial assistance programs for patients who have been prescribed Mvasi:

Amgen FIRST STEP Program

With this program, eligible patients who have private insurance will pay $0 for the first dose of Mvasi and $5 for each subsequent dose, with a maximum annual benefit of $20,000.

Amgen Safety Net Foundation

Patients with limited or no drug coverage, and patients with Medicare Part D insurance, who satisfy the income eligibility requirements may receive Mvasi for free.

Opdivo (nivolumab)

Drug company: Bristol-Myers Squibb
800-861-0048

Opdivo is a PD-1 inhibitor used alone, or in combination with Yervoy, for the treatment of patients age 12 years or older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan regimen.

Bristol-Myers Squibb Access Support offers 2 financial assistance programs for patients using Opdivo:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with out-of-pocket deductibles, copay, or coinsurance costs for eligible patients with private insurance who have been prescribed Opdivo. Patients pay a $25 copay, while BMS covers the remaining amount, up to $25,000 annually per medication (or $50,000 annually for 2 BMS medications used in combination).

Bristol-Myers Squibb Patient Assistance Foundation

Patients who don’t have public or private insurance that helps to pay for Opdivo may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $37,470 for an individual or $50,730 for a family of 2.

Stivarga (regorafenib) Tablets

Drug company: Bayer
866-639-2827

Stivarga is a kinase inhibitor used for patients with metastatic colorectal cancer who have previously received either chemotherapy, an anti-VEGF therapy, or if their cancer is RAS wild-type (no RAS mutation), an anti-EGFR therapy.

Bayer provides 2 financial assistance programs for patients using Stivarga:

Stivarga $0 Co-pay Program

Through this program, patients with private insurance will have a $0 copay for Stivarga, up to $25,000 per patient annually.

REACH Patient Assistance Program

Uninsured or underinsured patients who are prescribed Stivarga should contact the Resources for Expert Assistance and Care Helpline (REACH) services counselor to possibly qualify for free medication.

Vectibix (panitumumab)

Drug company: Amgen
888-427-7478

Vectibix is an EGFR antagonist used for patients with KRAS wild-type metastatic colorectal cancer as first-line treatment in combination with a chemotherapy regimen, or alone when their disease progresses after treatment with a chemotherapy regimen.

Amgen provides 2 financial assistance programs for patients using Vectibix:

Vectibix FIRST STEP Program

For patients with private insurance whose insurance covers Vectibix, this program ensures a copay of $0 for the first dose and $25 for each dose thereafter, with a maximum benefit of $10,000 per patient, annually.

Amgen Safety Net Foundation

Patients with limited or no drug coverage and patients with Medicare Part D who satisfy the income eligibility requirements can receive Vectibix for free through this nonprofit program from Amgen.

Xeloda (capecitabine) Tablets

Drug company: Genentech
866-422-2377

Xeloda is a nucleoside metabolic inhibitor with antineoplastic activity used as adjuvant treatment for patients with Dukes’ C colon cancer, and as a first-line therapy alone for patients with metastatic colorectal cancer when treatment with fluoropyrimidine therapy alone is preferred.

(Genentech does not provide a specific financial support program for Xeloda.)

Yervoy (ipilimumab)

Drug company: Bristol-Myers Squibb
800-861-0048

Yervoy is a human cytotoxic T-lymphocyte antigen 4–blocking antibody used, in combination with Opdivo, for the treatment of patients age 12 years or older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

Bristol-Myers Squibb Access Support offers 2 financial assistance programs for patients using Yervoy:

BMS Oncology Co-pay Assistance Program

The program provides financial assistance with the out-of-pocket deductibles, copay, or coinsurance costs for eligible, privately insured patients who have been prescribed Yervoy. Patients pay a $25 copay, and BMS covers the remaining amount, up to $25,000 annually per medication (or $50,000 annually for 2 BMS medications used in combination).

Bristol-Myers Squibb Patient Assistance Foundation

Patients who don’t have public or private insurance that helps to pay for Yervoy may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $36,420 for an individual or $49,380 for a family of 2.

Zaltrap (ziv-aflibercept)

Drug company: Sanofi
888-847-4877

Zaltrap, in combination with a chemotherapy regimen, is used for patients with metastatic colorectal cancer that is resistant to or has progressed after an Eloxatin-containing regimen.

The Sanofi Genzyme CareASSIST Patient Support Program provides 2 financial assistance programs for patients who are prescribed Zaltrap:

CareASSIST Copay Program

Eligible patients with commercial insurance may pay as little as $0 for Zaltrap. The Copay Program covers the drug cost up to a $25,000 benefit annually. Patients are responsible for any out-of-pocket costs for Zaltrap over the benefit limit. Patients must have commercial or private insurance, including state or federal employee plans and health insurance exchanges. This program has no income requirements to qualify.

CareASSIST Patient Support Program

Patients with no insurance coverage or no access to Zaltrap may be eligible for assistance through the Sanofi Genzyme CareASSIST Patient Support Program, including access to medication at no cost. Patients must not be eligible for government-based insurance, and their annual household income must not be more than $100,000, or 500% of the federal poverty level. Patients enrolled in Medicare Part B who have no supplemental insurance may be eligible to receive, Zaltrap through this program. If you do not meet Zaltrap requirements, contact a CareASSIST Patient Access Specialist at ASwww.sanoficareassist.com.

Table. Drugs Prescribed for Colorectal Cancer

  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services
    Drug name (generic name)
  • Avastin (bevacizumab) Injection
  • Drug company
  • Genentech
  • Indication
  • First-line or second-line therapy for metastatic colorectal cancer, in combination with IV-based chemotherapy

    Second-line treatment, in combination with a chemotherapy regimen, for metastatic colorectal cancer that progressed with a first-line Avastin-containing regimen
  • Patient support services
  • Genentech BioOncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331

    Drug name (generic name)
  • Camptosar (irinotecan hydrochloride injection)
  • Drug company
  • Pfizer
  • Indication
  • First-line therapy for metastatic carcinoma of the colon or rectum, in combination with 5-fluorouracil and leucovorin

    Second-line therapy for metastatic carcinoma of the colon or rectum, after chemotherapy
  • Patient support services
  • Pfizer Patient Assistance Program
    844-989-7284


    Drug name (generic name)
  • Erbitux (cetuximab)
  • Drug company
  • Eli Lilly
  • Indication
  • First-line treatment of metastatic colorectal cancer, in combination with chemotherapy

    Metastatic colorectal cancer, in combination with Camptosar

    Metastatic colorectal cancer, after chemotherapy or if unable to use Camptosar
  • Patient support services
  • Lilly PatientOne Co-pay Program
    866-472-8663

    Lilly Cares Foundation Patient Assistance Program
    800-545-6962

    Drug name (generic name)
  • Fusilev (levoleucovorin)
  • Drug company
  • Acrotech Biopharma
  • Indication
  • Palliative treatment of advanced metastatic colorectal cancer, in combination with chemotherapy
  • Patient support services
  • STAR Co-pay Assistance
    888-537-8277

    STAR Patient Assistance Program
    888-537-8277

    Drug name (generic name)
  • Khapzory (levoleucovorin) for Injection
  • Drug company
  • Acrotech Biopharma
  • Indication
  • Treatment of metastatic colorectal cancer, in combination with fluorouracil chemotherapy
    Treatment of osteosarcoma (bone cancer) after high-dose methotrexate therapy
  • Patient support services
  • STAR Co-pay Assistance
    888-537-8277
    STAR Patient Assistance Program
    888-537-8277


    Drug name (generic name)
  • Mvasi (bevacizumab-awwb)
  • Drug company
  • Amgen
  • Indication
  • Treatment of metastatic colorectal cancer, in combination with chemotherapy, or after disease progression with bevacizumab-containing regimen
  • Patient support services
  • Amgen FIRST STEP Program
    888-657-8371
    Amgen Safety Net Foundation
    888-762-6436



    Drug name (generic name)
  • Vectibix (panitumumab)
  • Drug company
  • Amgen
  • Indication
  • First-line therapy of metastatic colorectal cancer, in combination with chemotherapy

    Metastatic colorectal cancer, after chemotherapy
  • Patient support services
  • Vectibix FIRST STEP Program
    888-657-8371

    Amgen Safety Net Foundation
    888-762-6436

    Drug name (generic name)
  • Xeloda (capecitabine) Tablets
  • Drug company
  • Genentech
  • Indication
  • Adjuvant therapy for colon cancer, specifically Dukes’ C colon cancer

    First-line therapy for metastatic colorectal cancer
  • Patient support services
  • Genentech Patient Foundation
    888-941-3331



Last modified: February 4, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country